Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Envafolimab + Regorafenib

NCT06772233

Peking University · Phase 2 · Not yet recruiting · Enrollment 100

NCT06772233

Catalyst Primary completion. 07.30.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmPopulationDoseEstimandComparatorEfficacy

No efficacy figure is in this file for this study.